- Health & Pharmaceuticals›
- Pharmaceutical Products & Market›
U.S. brand and generic prescription drug revenue 2005-2018
Premium statistics
Industry-specific and extensively researched technical data (partially from exclusive partnerships).
A paid subscription is required for full access.
U.S. brand and generic prescription drug revenue 2005-2018
Proportion of branded versus generic prescription drug revenues in the United States from 2005 to 2018
by Matej Mikulic,
last edited
Sep 12, 2019
This statistic compares brand drug prescription revenues of branded and unbranded generics in the United States from 2005 to 2018. In 2005, some 81 percent of total U.S. prescription revenues were made through brand name medications. However, this share decreased to some 71 percent in 2013, but increased again to nearly 79 percent until 2018. Generics are copies or equivalents of once patent protected drugs, containing the same active ingredient, in the same amount, in the same form, dissolving at the same rate in equal amounts like the original.
Proportion of branded versus generic prescription drug revenues in the United States from 2005 to 2018
| Brands | Branded Generics | Unbranded Generics | |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Brands | Branded Generics | Unbranded Generics | |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
Exclusive Premium statistic
You need a Premium Account for unlimited access.
Full access to 1m statistics
Incl. source references
Available to download in PNG, PDF, XLS format
Premium Account
only $49 / month
*
Exclusive content
Exclusive Premium statistic
You need a Premium Account for unlimited access.
Full access to 1m statistics
Incl. source references
Available to download in PNG, PDF, XLS format
Premium Account
only $49 / month
*
© Statista 2019
About this statistic
Show source
Download
Settings
Share
Chart type
Datalabels
Share on Social Media
Download started
Please be patient - this may take a moment
Please be patient - this may take a moment
Description
Source
More information
by Matej Mikulic,
last edited
Sep 12, 2019
This statistic compares brand drug prescription revenues of branded and unbranded generics in the United States from 2005 to 2018. In 2005, some 81 percent of total U.S. prescription revenues were made through brand name medications. However, this share decreased to some 71 percent in 2013, but increased again to nearly 79 percent until 2018. Generics are copies or equivalents of once patent protected drugs, containing the same active ingredient, in the same amount, in the same form, dissolving at the same rate in equal amounts like the original.
- Show sources information
- Show publisher information
- Release date
- May 2019
- Region
- United States
- Survey time period
- 2005 to 2018
- Supplementary notes
-
Report reflects prescription-bound products including insulins and excluding other products such as OTC.
Includes prescriptions and insulins dispensed by chain and independent pharmacies, food store pharmacies, mail service pharmacies, and long-term
care facilities. Spending figures also include sales into hospitals, clinics, and other institutional settings.
Prescription counts are not adjusted for length of therapy. 90-day and 30-day prescriptions are both counted as one prescription.
This statistic was assembled from several IMS Health/QuintilesIMS/IQVIA reports.
Source
- Show sources information
- Show publisher information
- Release date
- May 2019
More information
- Region
- United States
- Survey time period
- 2005 to 2018
- Supplementary notes
-
Report reflects prescription-bound products including insulins and excluding other products such as OTC.
Includes prescriptions and insulins dispensed by chain and independent pharmacies, food store pharmacies, mail service pharmacies, and long-term
care facilities. Spending figures also include sales into hospitals, clinics, and other institutional settings.
Prescription counts are not adjusted for length of therapy. 90-day and 30-day prescriptions are both counted as one prescription.
This statistic was assembled from several IMS Health/QuintilesIMS/IQVIA reports.
Other statistics on the topic
Pharmaceutical Industry in the U.S.
+Pharmaceutical Products & Market
Pharmaceutical market: worldwide revenue 2001-2018
+Pharmaceutical Products & Market
Revenues of leading global generics manufacturers 2018
+Pharmaceutical Products & Market
Pfizer's revenue by segment 2014-2018
+Pharmaceutical Products & Market
Top branded biologic drugs in the U.S. that will go generic by 2028
Statista Accounts:
Access All Statistics. Starting from $588 / Year
Basic Account
Get to know the platform
You only have access to basic statistics.
This statistic is not included in your account!
Premium Account
Your perfect start with Statista
- Instant access to 1m statistics
- Download in XLS, PDF & PNG format
- Detailed references
$49 / Month *
Corporate Account
Full access
Corporate solution including all features.
* All products require an annual contract.
Prices do not include sales tax.
Prices do not include sales tax.
Leading companies trust Statista:
Related Studies: Available to Download in PDF or PPTX Format
All Information
in one Presentation
Generics and biosimilars
- 82 page/s
- English
- pptx
- Detailed references
Everything On "Generics and biosimilars" in One Document: Edited and Divided into Handy Chapters. Including Detailed References.
Other Reports & Dossiers
Statista is a great source of knowledge, and pretty helpful to manage the daily work.Christof Baron
CEO, MindShare Germany
Statistics on "Generics and biosimilars"
- Global overview
The most important statistics
- Revenue of the worldwide pharmaceutical market from 2001 to 2018 (in billion U.S. dollars)Pharmaceutical market: worldwide revenue 2001-2018
- Worldwide total generic prescription drug revenue from 2010 to 2024 (in billion U.S. dollars)Total worldwide generic prescription drug revenue 2010-2024
- Worldwide generic prescription drug revenue as a percent of total prescribed revenue from 2010 to 2024Global generic prescription drug revenues as share of prescribed revenue 2010-2024
- Worldwide total prescription drug revenue at risk from patent expiration from 2010 to 2024 (in billion U.S. dollars)*Patent expiration risks for total worldwide prescription drug revenue 2010-2024
- Top companies
The most important statistics
- Top generics manufacturers based on revenue in 2018 (in billion U.S. dollars)*Revenues of leading global generics manufacturers 2018
- Generic revenues of Teva Pharmaceutical Industries from 2016 to 2018, by region (in million U.S. dollars)Teva Pharmaceutical Industries' generic revenues by region 2016-2018
- Novartis AG's revenue from 2014 to 2018, by segment (in billion U.S. dollars)Novartis revenue 2014-2018 by segment
- Pfizer's revenue in 2014 and 2018, by segment (in million U.S. dollars)*Pfizer's revenue by segment 2014-2018
- U.S. market
The most important statistics
- Brand and generic prescription medication revenue in the U.S. from 2006 to 2018 (in billion U.S. dollars)*Brand and generic prescription medication revenue in the U.S. 2006-2018
- Proportion of branded versus generic prescription drug revenues in the United States from 2005 to 2018U.S. brand and generic prescription drug revenue 2005-2018
- Change in branded and generic medication spending in the United States from 2013 to 2018 (in billion U.S. dollars)*Spending change on branded and generic medicines in the U.S. 2013-2018
- Top generic drug companies by unbranded generics revenue in the U.S. in 2016-2017 (in billion U.S. dollars)*Unbranded generics revenue top corporations in U.S. 2016-2017
- Top companies based on unbranded generics U.S. market share during 2016-2017*Unbranded generics market share top corporations in U.S. 2016-2017
- Top 20 U.S. pharma products by dispensed prescriptions in 2018 (in millions)Top U.S. pharma products by prescriptions 2018
- Patent expiration
The most important statistics
- Small molecules sales at risk due to patent expirations in the U.S. from 2009 to 2022 (in billion U.S. dollars)Projected sales at risk due to patent expiry 2009-2022
- Leading pharmaceutical companies based on sales loss due to patent risk until year-end 2018Top pharma companies by sales loss due to patent loss until 2018
- Forecast of new brand and brand loss of exclusivity (LOE) impact on growth in developed pharmaceutical markets from 2018 to 2022 (in billion U.S. dollars)*Forecast of new brand and LOE impact on growth of developed pharma markets 2018-2022
- Selected top branded biologic drugs in the United States that will go generic between 2016 and 2028, by revenue (in billion U.S. dollars)*Top branded biologic drugs in the U.S. that will go generic by 2028
- Time from launching a brand drug to meeting a paragraph IV patent challenge in the U.S. from 1995 to 2014Time from brand drug launch to generic patent challenges U.S. 1995-2014
- Comparison of brand pre-expiry price and generic price of selected drugs in the United States as of 2015 (in U.S. dollars)Comparison of pre-expiry and generic price for drugs U.S. 2015
- Savings
The most important statistics
- Savings through generic drug usage in the United States from 2008 to 2018 (in billion U.S. dollars)Savings through generic drug usage in the U.S. 2008-2018
- Top generic drugs based on savings in the United States in 2018 (in million U.S. dollars)Total savings of top generic drugs in U.S. 2018
- Cost savings through generics in the United States in 2018, by select therapeutic area (in billion U.S. dollars)*Saving of U.S. costs through generic pharmaceuticals by select therapy 2018
- Savings through generic drug usage in the United States in 2018, by age group (in billion U.S. dollars)Savings through generic drug usage in the U.S., by age group 2018
- Savings through generic drug usage in the United States in 2018, by payer (in billion U.S. dollars)Savings through generic drug usage in the U.S., by payer 2018
- Percentage of savings through generic drug usage in the United States in 2018, by payerPercentage savings through generic drug usage in the U.S. by payer 2018
- Percentage of savings through generic drug usage in the United States in 2018, by age groupSavings through generic drug usage in the U.S., by age group share 2018
- Biosimilars
The most important statistics
- Cumulative potential biosimilars market in EU-5 countries and the U.S. between 2016 and 2020 (in billion euros)Cumulative potential biosimilars market in EU5 countries and the U.S. 2016-2020
- Number of biosimilars in development worldwide as of October 2017, by country Country-wise biosimilar pipelines number in development worldwide 2017
- Projected reduction in U.S. biosimilar direct spending on originator biologics as of 2018 (in billion U.S. dollars)Reduction in U.S. direct spending on originator biologics as of 2018
- Filgrastim market share of Neupogen and its U.S. biosimilar competitors from 2015 to 2017Share of filgrastim sales attributable to Neupogen or biosimilars US 2015-2017
- Insulin glargine market share of Lantus and its U.S. biosimilar competitor from 2015 to 2017Share of insuline glargine sales Lantus vs. biosimilar US 2015-2017
- Percentage of U.S. health care executives who foresee biosimilars reducing drug spend for specialty drugs in 2017-2020*Opinion on drug spending reduction due to biosimilars for specialty drugs 2017-2020
- Example of physician office payment for biosimilars in Medicare Part B as of 2019 (in U.S. dollars)*Physician office payment for biosimilars in Medicare Part B in 2019
Discover Statista
Need help with using Statista for your research?
Tutorials and first steps
Further Content: Statistics, Studies, and Topic Pages
Statistics
- U.S. spending growth on new brand specialty medicine by type 2014-2015
- U.S. spending on multiple sclerosis medicine by type 2010-2014
- U.S. spending on biosimilars by type 2014
- U.S. spending on specialty medicine by type 2014-2018
- Number of ANDA approvals in U.S. 2015-2017, by type
- U.S. total vs. generic dispensed prescription numbers 2017, by formulation
- Generic share of dispensed prescriptions by formulation U.S. 2012 vs. 2017
- Spending on dispensed total vs. generic prescriptions in the U.S. 2017
- Medicaid program savings through generic drug usage by U.S. state 2015
- Average number of approved ANDAs per month in U.S. 2009-2017
- Number of approved ANDAs in U.S. 2009-2017
- Drug dispensing cost share by drug type in public drug plans Canada 2014/15-2015/16
- Generic drug savings forecast for Canada 2015-2017
- Value of expiring patents in U.S. 2016-2019
- Share of drug dispensing costs in select public drug plans Canada 2015-2018
- Estimated daily use of cannabis among 18-25 years old in France 2016
- Italy: sales volume share of generic drugs 2013-2017
- Generic drug spending per capita in OECD countries 2018
- Antimicrobial drugs for livestock sales by route of administration in the U.S. 2017
- Opinions on generic prescription medication for treatment by country 2013
Studies
- Prescribed Drug Spending in Canada, 2018
- Recent Trends in Hospital Drug Spending and Manufacturer Shortages (2019)
- CDER 2018 New Drug Therapy Approvals
- Drug Use Among Seniors in Canada, 2016
- Prescribed Drug Spending in Canada, 2017
- CDER 2017 New Drug Therapy Approvals
- CDER New Drugs Program: 2018 Update
- Meds Entry Watch 2017
- Compass Rx - Annual Public Drug Plan Expenditure Report 2012/13
- Showdown over drug pricing
- Prescribed Drug Spending in Canada, 2013
- Prescribed Drug Spending in Canada, 2016
- Trends in Retail Prices of Prescription Drugs Widely Used by Older Americans: 2017 Year-En...
- Compass Rx - Annual Public Drug Plan Expenditure Report 2013/14
- CDER New Drug Review: 2016 Update
Statistics on "Generics and biosimilars"
- Pharmaceutical market: worldwide revenue 2001-2018
- Total worldwide generic prescription drug revenue 2010-2024
- Global generic prescription drug revenues as share of prescribed revenue 2010-2024
- Patent expiration risks for total worldwide prescription drug revenue 2010-2024
- Revenues of leading global generics manufacturers 2018
- Teva Pharmaceutical Industries' generic revenues by region 2016-2018
- Novartis revenue 2014-2018 by segment
- Pfizer's revenue by segment 2014-2018
- Brand and generic prescription medication revenue in the U.S. 2006-2018
- U.S. brand and generic prescription drug revenue 2005-2018
- Spending change on branded and generic medicines in the U.S. 2013-2018
- Unbranded generics revenue top corporations in U.S. 2016-2017
- Unbranded generics market share top corporations in U.S. 2016-2017
- Top U.S. pharma products by prescriptions 2018
- Projected sales at risk due to patent expiry 2009-2022
- Top pharma companies by sales loss due to patent loss until 2018
- Forecast of new brand and LOE impact on growth of developed pharma markets 2018-2022
- Top branded biologic drugs in the U.S. that will go generic by 2028
- Time from brand drug launch to generic patent challenges U.S. 1995-2014
- Comparison of pre-expiry and generic price for drugs U.S. 2015
- Savings through generic drug usage in the U.S. 2008-2018
- Total savings of top generic drugs in U.S. 2018
- Saving of U.S. costs through generic pharmaceuticals by select therapy 2018
- Savings through generic drug usage in the U.S., by age group 2018
- Savings through generic drug usage in the U.S., by payer 2018
- Percentage savings through generic drug usage in the U.S. by payer 2018
- Savings through generic drug usage in the U.S., by age group share 2018
- Cumulative potential biosimilars market in EU5 countries and the U.S. 2016-2020
- Country-wise biosimilar pipelines number in development worldwide 2017
- Reduction in U.S. direct spending on originator biologics as of 2018
- Share of filgrastim sales attributable to Neupogen or biosimilars US 2015-2017
- Share of insuline glargine sales Lantus vs. biosimilar US 2015-2017
- Opinion on drug spending reduction due to biosimilars for specialty drugs 2017-2020
- Physician office payment for biosimilars in Medicare Part B in 2019
- U.S. spending growth on new brand specialty medicine by type 2014-2015
- U.S. spending on multiple sclerosis medicine by type 2010-2014
- U.S. spending on biosimilars by type 2014
- U.S. spending on specialty medicine by type 2014-2018
- Number of ANDA approvals in U.S. 2015-2017, by type
- U.S. total vs. generic dispensed prescription numbers 2017, by formulation
- Generic share of dispensed prescriptions by formulation U.S. 2012 vs. 2017
- Spending on dispensed total vs. generic prescriptions in the U.S. 2017
- Medicaid program savings through generic drug usage by U.S. state 2015
- Average number of approved ANDAs per month in U.S. 2009-2017
- Number of approved ANDAs in U.S. 2009-2017
- Drug dispensing cost share by drug type in public drug plans Canada 2014/15-2015/16
- Generic drug savings forecast for Canada 2015-2017
- Value of expiring patents in U.S. 2016-2019
- Share of drug dispensing costs in select public drug plans Canada 2015-2018
- Estimated daily use of cannabis among 18-25 years old in France 2016
- Italy: sales volume share of generic drugs 2013-2017
- Generic drug spending per capita in OECD countries 2018
- Antimicrobial drugs for livestock sales by route of administration in the U.S. 2017
- Opinions on generic prescription medication for treatment by country 2013
Statista Accounts:
Access All Statistics. Starting from $588 / Year
Related topics
About Statista
Statista offers dossiers and reports on over 170 industries. With Statista you are always able to make informed decisions and boost your work efficiency.
Internet & Telecommunications
- Social Media
- E-Commerce
- Online Video & Entertainment
- Advertising & Marketing
Consumer Goods & FMCG
- Alcoholic Beverages
- Cleaning Products
- Cosmetics & Personal Care
- Food & Nutrition
Retail & Trade
- Health & Hygiene
- International Trade
- Shopping Behavior
- Sports & Leisure
Travel, Tourism & Hospitality
- Business Travel
- Leisure Travel
- Accomodation
- Restaurants
Society
- Demographics
- Economy
- Education & Science
- Politics & Government
Transportation & Logistics
- Aviation
- Rail Transport
- Vehicles & Road Traffic
- Water Transport
Save statistic in .XLS format
You can only download this statistic as a Premium user.
Save statistic in .PNG format
You can only download this statistic as a Premium user.
Save statistic in .PDF format
You can only download this statistic as a Premium user.
Show source references
As a Premium user you get access to the detailed source references and background information about this statistic.
Show details about this statistic
As a Premium user you get access to background information and details about the release of this statistic.
Bookmark statistics
As soon as this statistic is updated, you will immediately be notified via e-mail.
Change statistics options
You need at least a Premium Account to use this feature.
Exclusive Corporate feature
This feature is limited to our corporate solutions.
Please contact us to get started with full access to dossiers, forecasts, studies and international data.
Corporate Account
We use cookies to personalize contents and ads, offer social media features, and analyze access to our website. In your browser settings you can configure or disable this, respectively, and can delete any already placed cookies. For details, please see your browser’s Help section (by pressing F1). Please see our privacy statement for details about how we use data.